Study evaluates whether smoking cigarettes worsens clinical damage in PsA patients as it does in rheumatoid arthritis and ankylosing spondylitis.
An analysis of health records indicates that smoking is not associated with joint damage in psoriatic arthritis patients.
Investigators prospectively followed 1,107 subjects who participated in an observational cohort between 1978 and 2014. They evaluated each patient’s smoking status at baseline — i.e. each patient’s initial treatment for psoriatic arthritis — and put each patient into 1 of 3 categories: non-smoker, past smoker or smoker.
They then compared joint damage at each subsequent appointment among the 3 groups, defining clinical damage as “limitation of movement of more than 20% of the range that is not related to a joint effusion, the presence of flexion contractures, fused or flail joints, or evidence of surgery in a particular joint.”
The patient population was 55.6% male and had, a baseline, a mean age of 46 years, a mean duration of psoriasis of 17.4 years and a mean duration of psoriatic arthritis of 8.4 years. The majority of the cohort — 63.2% — had never been smokers when they first received treatment, while 24.4% were past smokers and 12.4% were current smokers. What’s more, 7.9% of the patients already had joint damage at baseline and 26% of them had dactylitis.
The investigators used a Cox regression analysis to look for factors that might predict time to joint damage, factors that included age, sex, dactylitis and smoking status, joint counts, treatment and human leukocyte antigen (HLA) B*27 status.
“Males, HLA-B*27 positivity, higher age at diagnosis of psoriatic arthritis, clinical damage at baseline, dactylitis and swollen joints were associated with a higher probability of developing clinically damaged joints whereas current and past-smokers at baseline were associated with a lower probability of developing clinically damaged joints compared to nonsmokers,” the investigators wrote in an abstract they presented at the Congress of the European League Against Rheumatism.
“Unlike what occurs in rheumatoid arthritis and ankylosing spondylitis, the clinical damage in psoriatic arthritis was not associated with smoking status but was associated with disease-specific features.”
A number of studies have found the connection between tobacco use and increased joint damage in patients with rheumatoid arthritis and ankylosing spondylitis. For example, a 2006 study that appeared in Rheumatology followed 100 patients with early rheumatoid arthritis for 2 years.
“A gradient of increase in disease activity was observed from never smokers to former smokers to current smokers during the 2 year of observation, defined by number of swollen joints, tender joints and visual analogue scale for pain (P<0.001, P=0.02 and P=0.005, respectively),” the authors of that study wrote.
Smoking has also been found to worsen outcomes among men with osteoarthritis. A 2007 study published in the Annals of Rheumatic Disease followed 159 men with symptomatic knee osteoarthritis for 30 months, comparing magnetic resonance imaging at baseline and at the study’s conclusion to measure disease progression.
After adjusting for age, body mass index and baseline cartilage scores, the study authors found that current smokers had an increased risk of cartilage loss at the medial tibiofemoral joint (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.0 to 5.4) and the patellofemoral joint (OR, 2.5; 95% CI, 1.1 to 5.7). Current smokers also had higher adjusted pain scores at baseline (60.5 v 45.0, p<0.05) and at followâ€up (59.4 v 44.3, p<0.05) than other men.